Study Finds Lemtrada Safe for MS Patients With Other Autoimmunity

Study Finds Lemtrada Safe for MS Patients With Other Autoimmunity

315575

Study Finds Lemtrada Safe for MS Patients With Other Autoimmunity

Other autoimmune conditions, particularly those characterized by the presence of anti-TPO antibodies, should not preclude patients with multiple sclerosis (MS) from receiving treatment with Lemtrada (alemtuzumab), according to an analysis of pooled data from clinical trials and post-market data. The study, “Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data,” was published in the Multiple Sclerosis Journal. Lemtrada, marketed by Sanofi-Genzyme, is a disease-modifying therapy that…

You must be logged in to read/download the full post.